Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 16/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 15/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254788 | 0.97 | ITGAL (0.36) | ITGALITGB2ICAM1KDM4ELMNA | |
| SCHEMBL14254783 | 0.90 | ITGAL (0.38) | ITGALITGB2ICAM1SMN1; SMN2 | |
| SCHEMBL4848030 | 0.89 | ITGAL (0.36) | ITGALITGB2ICAM1KDM4ELMNA | |
| SCHEMBL4886153 | 0.87 | ALDH1A1 (0.37) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4843410 | 0.86 | ITGAL (0.35) | ITGALITGB2ICAM1KDM4ELMNA | |
| SCHEMBL4850520 | 0.85 | ITGAL (0.38) | ITGALITGB2ICAM1 | |
| SCHEMBL4845213 | 0.84 | ITGAL (0.41) | ITGALITGB2ICAM1 | |
| SCHEMBL4843339 | 0.84 | ITGAL (0.43) | ITGALITGB2ICAM1 | |
| SCHEMBL14264022 | 0.84 | ITGAL (0.43) | ITGALITGB2ICAM1 | |
| SCHEMBL14254786 | 0.83 | ITGAL (0.38) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | ITGAL 6/4885ITGB2 1/4885ICAM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.